Related Experiment Videos
Lymphokine-mediated immunotherapy studies in mouse tumor systems
Cancer
|March 15, 1980
Summary
Human lymphokines derived from cell cultures demonstrated significant potential in treating mouse tumors. These lymphokine preparations induced tumor regression and prolonged survival, supporting their use in cancer immunotherapy research.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Investigating immunotherapeutic potential of lymphokines.
- Utilizing human lymphoblast cell cultures (RPMI 1788) as a source of lymphokines.
Purpose of the Study:
- To evaluate the antitumor effects of lymphokine preparations in mouse tumor models.
- To assess the potential of lymphokines in cancer immunotherapy.
Main Methods:
- Preparation of lymphokines from human lymphoblast cell cultures.
- Purification using Amicon filters, Sephadex G-25 column, affinity chromatography, and SDS-PAGE.
- Administration to mice with subcutaneous L-1210 tumors and B-16 melanoma.
Main Results:
- Lymphokine treatment led to inflammation-mediated tumor regression in both models.
- Significant tumor reduction, prolonged survival, and cures (20-40%) observed in L-1210 tumor-bearing mice.
- Tumor regression and survival prolongation also noted in B-16 melanoma models.
Conclusions:
- Mouse tumor models serve as effective bioassays for lymphokine antitumor activity.
- Human lymphokine preparations show promise for cancer immunotherapy.
- Further quantification of lymphokine potential in human tumor immunotherapy is supported.